Remy Delva
Overview
Explore the profile of Remy Delva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fizazi K, Le Teuff G, Flechon A, Pagliaro L, Mardiak J, Geoffrois L, et al.
J Clin Oncol
. 2024 Aug;
42(28):3270-3276.
PMID: 39167741
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy...
2.
Rajpar S, Ibrahim T, Carmel A, Merabet Z, Vielh P, Foulon S, et al.
Eur Urol Oncol
. 2024 Jul;
PMID: 39034169
Background And Objective: Docetaxel has become a standard component of care for advanced prostate cancer (PC); however, its benefits are not universal among patients. A subset of PC cases exhibit...
3.
Orlando V, Drubay D, Lavaud P, Faivre L, Lesaunier F, Delva R, et al.
Clin Genitourin Cancer
. 2023 Jun;
21(5):615.e1-615.e8.
PMID: 37263910
Introduction: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases...
4.
Gluszak C, De Vries-Brilland M, Seegers V, Baroin C, Kieffer H, Delva R, et al.
Oncologist
. 2022 Apr;
27(4):328-333.
PMID: 35380718
Background: Iron deficiency (ID) is very common in patients with solid tumors and may cause symptoms such as fatigue. However, its impact on clinical outcomes is poorly described. The aim...
5.
Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, et al.
Eur Urol
. 2021 Nov;
81(3):234-240.
PMID: 34789394
Background: The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have...
6.
Cancel M, Fromont G, Blonz C, Chevreau C, Rioux-Leclercq N, Laguerre B, et al.
Eur J Cancer
. 2021 Oct;
158:1-11.
PMID: 34619467
Background: Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib...
7.
Chevreau C, Massard C, Flechon A, Delva R, Gravis G, Lotz J, et al.
Cancer Med
. 2021 Mar;
10(7):2250-2258.
PMID: 33675184
Background: High-dose chemotherapy (HDCT) with TI-CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug...
8.
Moeung S, Chevreau C, Marsili S, Massart C, Flechon A, Delva R, et al.
Pharm Res
. 2020 Jul;
37(7):147.
PMID: 32676789
Background: Etoposide dosing is based on body surface area. We evaluated if further dose individualization would be required for high dose (HD) etoposide within the TI-CE (taxol, ifosfamide, carboplatin, and...
9.
Voog E, Campillo-Gimenez B, Elkouri C, Priou F, Rolland F, Laguerre B, et al.
Int J Cancer
. 2019 Jul;
146(6):1643-1651.
PMID: 31318983
The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy. Outside of...
10.
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard A, et al.
JAMA Oncol
. 2019 Feb;
5(5):623-632.
PMID: 30703190
Importance: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective: To...